GLPBio

STC-15

Catalog No.: GC73680Purity:>98.00%
COASDSData Sheet
STC-15 is a potent, selective and orally active inhibitor of RNA methyltransferase METTL3, with an IC50 value of 6.1nM.

Products are for research use only. Not for human use. We do not sell to patients.

STC-15
Cas No.: 2648257-56-9
10mM (in 1mL DMSO)In Stock
$73.00
1
1mgIn Stock
$40.00
1
5mgIn Stock
$80.00
1
10mgIn Stock
$120.00
1
25mgIn Stock
$220.00
1
50mgIn Stock
$352.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

STC-15 is a potent, selective and orally active inhibitor of RNA methyltransferase METTL3, with an IC50 value of 6.1nM [1]. STC-15 can activate the innate immune pathway and modify the tumor microenvironment (TME), transforming the TME from an immunosuppressive, tumor-promoting state to an immunostimulatory, anti-tumor state[2]. STC-15 has been widely used in inhibiting tumor progression in cell and animal models, as well as in the development of novel combined therapies[3].

In vitro, STC-15 treatment combined with HJP-178 for 7 days significantly inhibited the proliferation of SKOV-3 cells, with IC50 values of 1.194μM[4]. STC-15 treatment (0.5µM) for 48h induced the expression of endogenous IFN signaling in the Caov3 ovarian cell line[5].

In vivo, STC-15 treatment via intraperitoneal injection at a dose of 30mg/kg/day for 2 days significantly reduced the cellular level of m6A in peripheral blood mononuclear cells (PBMC) of SD rats[6].

References:
[1] Tang H, Zhang R, Zhang A. Small-molecule inhibitors targeting RNA m6A modifiers for cancer therapeutics: latest advances and future perspectives[J]. Journal of Medicinal Chemistry, 2025, 68(17): 18114-18142.
[2] Ofir-Rosenfeld Y, Vasiliauskaitė L, Obacz J, et al. Abstract C077: STC-15, a small molecule inhibitor of the RNA methyltransferase METTL3, activates anti-tumor immunity and reshapes the tumor microenvironment[J]. Molecular Cancer Therapeutics, 2023, 22(12_Supplement): C077-C077.
[3] Vasiliauskaite L, Ofir-Rosenfeld Y, Albertella M, et al. Abstract A18: STC-15, a novel METTL3 inhibitor, and its combination with Venetoclax confer anti-tumour activity in AML models[J]. Blood Cancer Discovery, 2023, 4(3_Supplement): A18-A18.
[4] Ou Y J, Liu B J, Xuan Y F, et al. The combination of BET and METTL3 inhibitors elicits synergistic antitumor effects in ovarian cancer cells via reducing SP1 and BCL-2 expression[J]. Life Sciences, 2025, 368: 123505.
[5] Ofir-Rosenfeld Y, Vasiliauskaitė L, Obacz J, et al. STC-15, a small molecule inhibitor of the RNA methyltransferase METTL3, activates anti-tumor immunity and reshapes the tumor microenvironment[C]//MOLECULAR CANCER THERAPEUTICS. 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH, 2023, 22(12).
[6] Dutheuil G, Oukoloff K, Korac J, et al. Discovery, optimization, and preclinical pharmacology of EP652, a METTL3 inhibitor with efficacy in liquid and solid tumor models[J]. Journal of Medicinal Chemistry, 2025, 68(3): 2981-3003.

Protocol

Cell experiment [1]:

Cell lines

SKOV-3 cells

Preparation Method

SKOV-3 cells were cultured in DMEM medium containing 10% fetal bovine serum (FBS) at 37℃ in the presence of 5% CO2. SKOV-3 (1500 cells/well) were seeded into six-well plates for the formation of colonies. Cells were cultured overnight and treated with different concentrations of STC-15 (1.562, 3.125, 6.25, 12.5, 25, and 50μM) for another 7 days. After being fixed, the cell colonies were stained with sulforhodamine B (SRB) and the numbers of colonies per well were counted.

Reaction Conditions

1.562, 3.125, 6.25, 12.5, 25, and 50μM; 7 days

Applications

STC-15 treatment suppressed the cell proliferation of SKOV-3 cells in a dose-dependent manner.
Animal experiment [2]:

Animal models

Male SD rats

Preparation Method

Male SD rats were group-housed in cages with bedding material, and were housed in a room with controlled humidity (50±10%) and temperature (25±3°C) under a 12/12h light/dark cycle. All mice were adaptively fed for one week. The rats were intraperitoneally injected with 30mg/kg/day dose of STC-15 or 3mg/kg/day dose of EP652 for two days. PBMC samples were collected from the rats for analysis.

Dosage form

30mg/kg/day for 2 days; i.p.

Applications

STC-15 treatment significantly reduced the cellular level of m6A in PBMCs of SD rats.

References:
[1] Ou Y J, Liu B J, Xuan Y F, et al. The combination of BET and METTL3 inhibitors elicits synergistic antitumor effects in ovarian cancer cells via reducing SP1 and BCL-2 expression[J]. Life Sciences, 2025, 368: 123505.
[2] Dutheuil G, Oukoloff K, Korac J, et al. Discovery, optimization, and preclinical pharmacology of EP652, a METTL3 inhibitor with efficacy in liquid and solid tumor models[J]. Journal of Medicinal Chemistry, 2025, 68(3): 2981-3003.

Product Documents

Purity:>98.00%Appearance:A solid
COASDSData Sheet

Chemical Properties

CAS No.
2648257-56-9
Molecular Formula
C24H25N5O2
Molecular Weight
415.49
Solubility
DMSO : 116.67 mg/mL (280.80 mM; Need ultrasonic)
Storage
-20°C
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for STC-15

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%